Pertuzumab biosimilar (CTTQ)

帕妥珠单抗生物类似药（正大天晴）

Report date: 2024/12/31 11:07:09

Base Information

Drug NamePertuzumab biosimilar (CTTQ)
Drug Alias Name帕妥珠单抗生物仿制药（正大天晴）帕乐坦TQB-2440
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2024/12/17
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Inactive CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01XC13
Related LinksN/A